In NSCLC mouse model, specifically it was shown that in vivo injection of MRX34 generates the lower expression of PD-L1, but MRX34 can also boost tumor infiltration of CD8+ T cells and reduce CD8+PD1+ T cells (172). This evidence concerns the gene CD8A and non-small cell lung carcinoma.